Qualigen leads NanoSynex bridge round for rapid AST technology

AIxCrypto Holdings, Inc.

Qualigen is first investor in NanoSynex's 2025 bridge round of up to $500K.
NanoSynex's AST halves test time; global market projected at $4.7B by 2027.
US AST market expected $1.6B; NanoSynex targets EU approval 2027, US 2028.
NanoSynex holds 4 patents; product has competitive advantages and pipeline.
CEO says investment supports better antibiotic use and robust diagnostics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.